Understanding Changes in Geron’s Risk Factors
October 05 2021 - 06:10AM
TipRanks
Geron Corporation (GERN) is an American biopharmaceutical company.
Its imetelstat drug candidate is in Phase 3 clinical trials and has
been granted Fast Track designation by the FDA. Geron plans to
apply for marketing approval for the drug candidate in the U.S. in
2023 and also plans to seek marketing authorization in Europe.
Let’s take a look at Geron’s latest financial performance,
corporate updates, and changes in risk factors. (See Geron Corp
stock charts on TipRanks). Q2 Financial Results Geron reported
revenue of $107,000 for Q2 2021, compared to $43,000 in the same
quarter last year. The company’s main sources of revenue currently
are license fees and royalties.
https://www.tipranks.com/news/understanding-changes-in-gerons-risk-factors?utm_source=advfn.com&utm_medium=referral
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2022 to May 2022
Geron (NASDAQ:GERN)
Historical Stock Chart
From May 2021 to May 2022